Skip to content
    Clinical Trials

    Phase II Trial of First-line Axitinib plus Nivolumab in Patients with Advanced Mucosal Melanoma

    Lochrin et alClinical Cancer Research

    Phase II Trial of First-line Axitinib plus Nivolumab in Patients with Advanced Mucosal Melanoma
    In a single-center, investigator-initiated phase II trial, investigators evaluated first-line nivolumab administered every 4 weeks in combination with axitinib twice daily in a Western population with previously untreated unresectable or metastatic mucosal melanoma. Mucosal melanoma is a rare melanoma subtype associated with poor response rates and inferior outcomes following standard immunotherapy, and vascular endothelial growth factor (VEGF) pathway activation is considered a potential mediator of immune resistance. The primary trial endpoint was objective response rate (ORR) assessed by RECIST v1.1. In addition, a sequential phase Ib exploratory cohort evaluated the safety of treatment intensification using either ipilimumab or stereotactic body radiotherapy (SBRT) upon disease progression.
    Among 20 evaluable patients, nivolumab plus axitinib produced an ORR of 45% (95% CI, 23–68), comprising 4 complete responses (20%) and 5 partial responses (25%). The median duration of response reached 21 months (95% CI, 8.6–NR). Median progression-free survival was 6.4 months (95% CI, 3.5–NR), and median overall survival was not reached. Safety analysis revealed grade 3 to 5 treatment-related adverse events in 67% of participants, including two treatment-related deaths. Among the 7 patients escalated to triplet therapy upon progression (ipilimumab, n = 5; SBRT, n = 2), treatment was feasible with no unexpected toxicities observed. The study concluded that nivolumab plus axitinib demonstrated meaningful activity in advanced mucosal melanoma, supporting further investigation in randomized clinical trials.

    Key Takeaways

    • First-line nivolumab plus axitinib achieved an objective response rate of 45% (95% CI, 23–68%), with a 20% complete response rate and a median duration of response of 21 months (95% CI, 8.6–NR), in patients with advanced mucosal melanoma.
    • Grade 3 to 5 treatment-related adverse events occurred in 67% of patients, including two treatment-related deaths.
    • Median progression-free survival was 6.4 months (95% CI, 3.5–NR), median overall survival was not reached, and sequential treatment escalation to triplet therapy with ipilimumab (n = 5) or SBRT (n = 2) showed no unexpected toxicities.
    Read the original sourceClinical Cancer Research